Bedrijfsoverzicht
Cyclerion Therapeutics, Inc. is a biopharmaceutical enterprise focused on the development of therapeutic treatments for serious diseases utilizing novel soluble guanylate cyclase (sGC) stimulators that target both the central nervous system and the periphery. The company operates within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high research and development costs and significant regulatory hurdles before products reach the market. As a small-cap entity, Cyclerion holds a market capitalization of $12.60M and generated annual revenue of $2.07M in the trailing twelve months, employing only 1 individual according to the available data. These financial figures indicate that the company operates with a very limited operational footprint and limited financial resources, positioning it as a micro-cap biotechnology firm that relies heavily on external capital to fund its pipeline of novel sGC stimulators like Olinciguat. The disparity between the company's small market cap and its revenue base suggests that the market values the potential of its drug candidates more than its current revenue generation capabilities, a common characteristic for early-stage biopharmaceutical companies that have yet to achieve widespread commercialization or regulatory approval for their primary assets.
Financiële gezondheid
The company reported revenue of $2.07M for the trailing twelve months, accompanied by a net income loss of $-3,528,000, while EBITDA data is not available for this period. The substantial gap between the modest revenue figure of $2.07M and the significant net income deficit of $-3.53M reveals a cost structure where operating expenses, likely dominated by research and development and general administrative costs, far exceed current sales revenue. Free cash flow stands at $-2,894,125, indicating that the company is burning cash rapidly to sustain its operations and pipeline development, which limits its financial flexibility and necessitates continuous access to capital markets or private funding. The company maintains a cash balance of $3.24M against zero total debt, resulting in a debt-to-equity ratio that is not applicable due to the absence of debt. Despite holding $3.24M in cash reserves, the operating margin of -81.8% and profit margin of -170.1% highlight severe inefficiencies in converting revenue into profit, while the gross margin of 53.8% suggests that the cost of goods sold for its products is managed relatively well compared to the high overheads inherent in the biotechnology sector. The current ratio of 5.15 indicates a strong short-term liquidity position, as the company possesses more than five times the current assets required to cover its current liabilities, providing a substantial buffer against immediate financial obligations. Return on Equity is recorded at -39.3% and Return on Assets at -31.8%, metrics that demonstrate the company is currently destroying value rather than generating returns, reflecting the typical financial reality of pre-revenue or early-revenue biotechnology firms investing heavily in future growth potential at the expense of current profitability.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable due to the lack of earnings, whereas the forward P/E stands at -2.22, a metric that reflects the market's pricing of expected future earnings relative to the current stock price in a loss-making environment. The price-to-book ratio is 1.22, indicating that the market is valuing the company at 22% above its book value, which may suggest confidence in the intangible assets and pipeline value despite the lack of current profitability. The price-to-sales ratio is 6.08, and the EV/EBITDA is not applicable; these alternative valuation metrics suggest that investors are pricing the stock based on revenue multiples and potential asset value rather than cash flow generation or earnings power. Over the past year, the stock has traded between a 52-week low of $1.03 and a 52-week high of $8.48, and without the specific current share price in the provided facts, the exact percentage distance from the high or low cannot be calculated, but the range demonstrates high price volatility typical of small-cap biotech stocks. The beta is 0.89, which implies that the stock's price volatility is slightly lower than the broader market, suggesting that Cyclerion's price movements are somewhat less sensitive to general market fluctuations than the average large-cap equity.
Growth & Income
Revenue growth year-over-year is recorded at -43.2%, while earnings growth is not applicable as the company has not achieved positive earnings in the recent period. The negative revenue growth indicates a contraction in sales, which is significant for a company with a limited revenue base, and since earnings growth is not applicable, it is impossible to determine if earnings are growing faster or slower than revenue in a traditional sense, as the company is currently unprofitable. The company does not pay a dividend, evidenced by a dividend yield of not applicable and a payout ratio of 0.0%, meaning that all available earnings or cash flows are retained within the company to fund operations and research rather than being distributed to shareholders. Consequently, the overall growth and income profile is defined by negative revenue expansion and a complete reinvestment strategy aimed at developing its therapeutic portfolio, rather than providing income through dividends or consistent earnings growth.